Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Glucagon-Like Peptide 1 (GLP-1) Market Report 20262035
Professor Jastreboffs research contributions include: Principal investigator for GLP3 phase 2 obesity trial demonstrating 24.2% weight loss Leadership in clinical research examining triple hormone receptor agonists Extensive investigations of incretin-based therapies for obesity and metabolic disease Pioneering work on combination approaches to weight management Studies examining neurobiological mechanisms underlying obesity pharmacotherapy Her work has helped establish GLP3 as one of the most promising next-generation obesity treatments in clinical development, contributing to the scientific foundation for multi-pathway metabolic interventions
Broad Agency Announcements (BAAs) DoD SBIR 24.3 & DoD STTR 24.C are NOW in Pre-Release
What is Dihexa
The anti-inflammatory properties of BPC-157 appear distinct from standard anti-inflammatory medications
